Human intestinal barrier function in health and disease

Clinical and Translational Gastroenterology

Volumn 7, Issue 10, 2016, Pages

  König, Julia ^a   Wells, Jerry ^b   Cani, Patrice D ^c   García Ródenas, Clara L ^d   MacDonald, Tom ^e   Mercenier, Annick ^d   Whyte, Jacqueline ^f   Troost, Freddy ^g   Brummer, Robert Jan ^a  

^a Örebro University   (Sweden)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d NESTLÉ RESEARCH CENTER   (Switzerland)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f International Life Sciences Institute of Europe   (Belgium)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; ACETYLSALICYLIC ACID; ELECTROLYTE; ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICLE; BLEEDING; CELIAC DISEASE; CONSTIPATION; ENTEROPATHY; EPIGASTRIC PAIN; EROSION; ERYTHEMA; FOOD ALLERGY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRACT; HUMAN; ILEUS; INFECTION; INFLAMMATORY BOWEL DISEASE; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE ULCER; IRRITABLE COLON; MUCOSA INFLAMMATION; NONHUMAN; NUTRIENT; OBESITY; PERFORATION; PERMEABILITY BARRIER; PRIORITY JOURNAL; SURFACE AREA; ULCER; WATER ABSORPTION;

EID: 85013411165     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2016.54     Document Type: Article

References (186)

1. Bischoff SC, Barbara G, Buurman W et al. Intestinal permeability-a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 1.
2. Dörfel M, Huber O. Modulation of tight junction structure and function by kinases and phosphatases targeting occludin. Biomed Res Int 2012; 2012: 807356.
3. Dörfel MJ, Huber O. A phosphorylation hotspot within the occludin C-terminal domain. Ann NY Acad Sci 2012; 1257: 38-44.
4. Petecchia L, Sabatini F, Usai C et al. Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway. Lab Invest 2012; 92: 1140-1148.
5. Al-Sadi R, Guo S, Ye D et al. TNF-A modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1. Am J Pathol 2013; 183: 1871-1884.
6. Al-Sadi R, Guo S, Ye D et al. Mechanism of IL-1b modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation. J Immunol 2013; 190: 6596-6606.
7. Zheng B, Cantley LC. Regulation of epithelial tight junction assembly and disassembly by AMP-activated protein kinase. Proc Natl Acad Sci USA 2007; 104: 819-822.
8. Ye J, Tsukamoto T, Sun A et al. A role for intracellular calcium in tight junction reassembly after ATP depletion-repletion. Am J Physiol Physiol 1999; 277: F524-F532.
9. Rao R. Oxidative stress-induced disruption of epithelial and endothelial tight junctions. Front Biosci 2008; 13: 7210-7226.
10. Turner JR, Rill BK, Carlson SL et al. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol Physiol 1997; 273: C1378-C1385.
11. Lapointe TK, O'Connor PM, Buret AG. The role of epithelial malfunction in the pathogenesis of enteropathogenic E. coli-induced diarrhea. Lab Invest 2009; 89: 964-970.
12. Frankel G, Phillips AD. Attaching effacing Escherichia coli and paradigms of Tir-triggered actin polymerization: getting off the pedestal. Cell Microbiol 2008; 10: 549-556.
13. Muza-Moons MM, Schneeberger EE, Hecht GA. Enteropathogenic Escherichia coli infection leads to appearance of aberrant tight junctions strands in the lateral membrane of intestinal epithelial cells. Cell Microbiol 2004; 6: 783-793.
14. Simonovic I, Arpin M, Koutsouris A et al. Enteropathogenic Escherichia coli activates ezrin, which participates in disruption of tight junction barrier function. Infect Immun 2001; 69: 5679-5688.
15. Manjarrez-Hernandez HA, Amess B, Sellers L et al. Purification of a 20 kDa phosphoprotein from epithelial cells and identification as a myosin light chain phosphorylation induced by enteropathogenic Escherichia coli and phorbol ester. FEBS Lett 1991; 292: 121-127.
16. Kaper JB, Nataro JP, Mobley HLT. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2: 123-140.
17. Amasheh S, Meiri N, Gitter AH et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 2002; 115: 4969-4976.
18. Rosenthal R, Milatz S, Krug SM et al. Claudin-2, a component of the tight junction, forms a paracellular water channel. J Cell Sci 2010; 123: 1913-1921.
19. Zeissig S, Bürgel N, Günzel D et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007; 56: 61-72.
20. Mankertz J, Amasheh M, Krug SM et al. TNFalpha up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling. Cell Tissue Res 2009; 336: 67-77.
21. Dubreuil JD. The whole Shebang: The gastrointestinal tract, Escherichia coli enterotoxins and secretion. Curr Issues Mol Biol 2012; 14: 71-82.
22. Okhuysen PC, DuPont HL. Enteroaggregative Escherichia coli (EAEC): A cause of acute and persistent diarrhea of worldwide importance. J Infect Dis 2010; 202: 503-505.
23. Dubreuil JD. Escherichia coli STb toxin and colibacillosis: knowing is half the battle. FEMS Microbiol Lett 2008; 278: 137-145.
24. Ngendahayo MC, Dubreuil JD. Escherichia coli heat-stable toxin b impairs intestinal epithelial barrier function by altering tight junction proteins. Infect Immun 2013; 81: 2819-2827.
25. Bagnoli F, Buti L, Tompkins L et al. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc Natl Acad Sci USA 2005; 102: 16339-16344.
26. Fasano A, Baudry B, Pumplin DW et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991; 88: 5242-5246.
27. Gopalakrishnan S, Pandey N, Tamiz AP et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm 2009; 365: 121-130.
28. Goldblum SE, Rai U, Tripathi A et al. The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J 2011;25:144-158.
29. Karczewski J, Troost FJ, Konings I et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Liver Physiol 2010; 298: G851-G859.
30. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004; 28: 405-440.
31. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007; 5: 97-105.
32. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203-1207.
33. Nenci A, Becker C, Wullaert A et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446: 557-561.
34. Guenther C, Martini E, Wittkopf N et al. Caspase-8 regulates TNF-[agr]-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335-339.
35. Takahashi N, Vereecke L, Bertrand MJM et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 2014; 513: 95-99.
36. Heazlewood CK, Cook MC, Eri R et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008; 5: e54.
37. Kaser A, Lee AH, Franke A et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008; 134: 743-756.
38. Van der Sluis M, De Koning BAE, de Bruijn ACJM et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129.
39. Sovran B, Loonen LMP, Lu P et al. IL-22-STAT3 pathway plays a key role in the maintenance of ileal homeostasis in mice lacking secreted mucus barrier. Inflamm Bowel Dis 2015; 21: 531-542.
40. Kuehn R, Loehler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
41. Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045.
42. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
43. Silverberg MS, Cho JH, Rioux JD et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet 2009; 41: 216-220.
44. Schaeppi MG, Smith V V, Goldblatt D et al. Colitis in chronic granulomatous disease. Arch Dis Child 2001; 84: 147-151.
45. Brennan GT, Melton SD, Spechler SJ et al. Clinical implications of histologic abnormalities in ileocolonic biopsies of patients with Crohn's disease in remission. J Clin Gastroenterol 2016; http://journals.lww.com/jcge/Abstract/publishahead/Clinical-Implications-of-Histologic-Abnormalities.98321.aspx.
46. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996; 110: 1395-1403.
47. Sinha A, Nightingale JMD, West KP et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-357.
48. Salim SY, Soederholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 362-381.
49. Miquel S, Martin R, Rossi O et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013; 16: 255-261.
50. Finnie IA, Dwarakanath AD, Taylor BA et al. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995; 36: 93-99.
51. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-1728.
52. Wang J, Wang X, Yang H et al. Contribution of the IBD5 locus to inflammatory bowel disease: A meta-analysis. Hum Genet 2011; 129: 597-609.
53. Noble CL, Nimmo ER, Drummond H et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 2005; 129: 1854-1864.
54. Tremelling M, Waller S, Bredin F et al. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis 2006; 12: 178-184.
55. Anderson CA, Boucher G, Lees CW et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252.
56. Darsigny M, Babeu JP, Dupuis AA et al. Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice. PLoS One 2009; 4: e7609.
57. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
58. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
59. Strober W, Asano N, Fuss I et al. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease. Immunol Rev 2014; 260: 249-260.
60. Brooke MA, Longhurst HJ, Plagnol V et al. Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. Gut 2012; 63: 96-104.
61. Delvaux M. Functional bowel disorders and irritable bowel syndrome in Europe. Aliment Pharmacol Ther 2003; 18: 75-79.
62. Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: The past, the present and the future. J Gastroenterol Hepatol 2011; 26: 94-101.
63. Fond G, Loundou A, Hamdani N et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2014; 264: 651-660.
64. Levy RL, Olden KW, Naliboff BD et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1447-1458.
65. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012; 18: 258.
66. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review. J Gastroenterol 2011; 46: 421-431.
67. Steck N, Mueller K, Schemann M et al. Republished: bacterial proteases in IBD and IBS. Postgrad Med J 2013; 89: 25-33.
68. Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2000; 62: 28-36.
69. McKernan DP, Gaszner G, Quigley EM et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-1052.
70. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
71. Han W, Lu X, Jia X et al. Soluble mediators released from PI-IBS patients' colon induced alteration of mast cell: involvement of reactive oxygen species. Dig Dis Sci 2012; 57: 311-319.
72. Chassard C, Dapoigny M, Scott KP et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-838.
73. Koenig J, Brummer RJ. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes 2014; 5: 247-261.
74. Rajilic-Stojanovic M, Biagi E, Heilig HGHJ et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801.
75. Saulnier DM, Riehle K, Mistretta T et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1782-1791.
76. Sundin J, Rangel I, Fuentes S et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 2015; 41: 342-351.
77. Brint EK, MacSharry J, Fanning A et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-336.
78. Zhou Q, Zhang B, Nicholas Verne G. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-46.
79. Zhou Q, Souba WW, Croce CM et al. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010; 59: 13.
80. Mujagic Z, Ludidi S, Keszthelyi D et al. Small intestinal permeability is increased in diarrhea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther 2014; 40: 288-297.
81. Hamer HM, Jonkers DMAE, Bast A et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009; 28: 88-93.
82. Hamer HM, Jonkers D, Venema K et al. Review article: The role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119.
83. Wallon C, Yang PC, Keita AV et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008; 57: 50-58.
84. Vanuytsel T, van Wanrooy S, Vanheel H et al. Psychological stress and corticotropinreleasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014; 63: 1293-1299.
85. Larauche M. Novel insights in the role of peripheral corticotropin-releasing factor and mast cells in stress-induced visceral hypersensitivity. Neurogastroenterol Motil 2012; 24: 201-205.
86. Hubbard CS, Labus JS, Bueller J et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. J Neurosci 2011; 31: 12491-12500.
87. Eckel RH. Obesity. Circulation 2005; 111: 257-259.
88. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-246.
89. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
90. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
91. Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110: 9066-9071.
92. Everard A, Geurts L, Caesar R et al. Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status. Nat Commun 2014; 5: 5648.
93. Muccioli GG, Naslain D, Backhed F et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010; 6: 392.
94. Chassaing B, Koren O, Goodrich JK et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015; 519: 92-96.
95. Cani PD, Van Hul M. Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr Opin Biotechnol 2015; 32: 21-27.
96. Erridge C, Attina T, Spickett CM et al. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-1292.
97. Amar J, Burcelin R, Ruidavets JB et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 1219-1223.
98. Laugerette F, Vors C, Geloen A et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011; 22: 53-59.
99. Deopurkar R, Ghanim H, Friedman J et al. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care 2010; 33: 991-997.
100. Ghanim H, Abuaysheh S, Sia CL et al. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009; 32: 2281-2287.
101. Anderson PD, Mehta NN,Wolfe ML et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007; 92: 2272-2279.
102. Creely SJ, McTernan PG, Kusminski CM et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E740-E747.
103. Pussinen PJ, Havulinna AS, Lehto M et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34: 392-397.
104. Al-Attas OS, Al-Daghri NM, Al-Rubeaan K et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009; 8: 20.
105. Nolan JP. The role of endotoxin in liver injury. Gastroenterology 1975; 69: 1346-1356.
106. Nolan JP, Leibowitz AI. Endotoxins in liver disease. Gastroenterology 1978; 75: 765-766.
107. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
108. Farhadi A, Gundlapalli S, Shaikh M et al. Susceptibility to gut leakiness: A possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008; 28: 1026-1033.
109. Miele L, Valenza V, La TG et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
110. Gummesson A, Carlsson LM, Storlien LH et al. Intestinal permeability is associated with visceral adiposity in healthy women. Obesity 2011; 19: 2280-2282.
111. Brignardello J, Morales P, Diaz E et al. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther 2010; 32: 1307-1314.
112. Schulzke JD, Bentzel CJ, Schulzke I et al. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 1998; 43: 435-441.
113. Montalto M, Cuoco L, Ricci R et al. Immunohistochemical analysis of ZO-1 in the duodenal mucosa of patients with untreated and treated celiac disease. Digestion 2002; 65: 227-233.
114. Pizzuti D, Bortolami M, Mazzon E et al. Transcriptional downregulation of tight junction protein ZO-1 in active celiac disease is reversed after a gluten-free diet. Dig Liver Dis 2004; 36: 337-341.
115. Bjarnason I, Peters T, Veall N. A persistent defect in intestinal permeability in celiac disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet 1983; 321: 323-325.
116. Duerksen DR, Wilhelm-Boyles C, Parry DM. Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet. Dig Dis Sci 2005; 50: 785-790.
117. Heyman M, Abed J, Lebreton C et al. Intestinal permeability in celiac disease: insight into mechanisms and relevance to pathogenesis. Gut 2012; 61: 1355-1364.
118. Van Elburg RM, Uil JJ, Mulder CJ et al. Intestinal permeability in patients with celiac disease and relatives of patients with celiac disease. Gut 1993; 34: 354-357.
119. Drago S, El Asmar R, Di Pierro M et al. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006; 41: 408-419.
120. Sander GR, Cummins AG, Powell BC. Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett 2005; 579: 4851-4855.
121. Clemente MG, De Virgiliis S, Kang JS et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003; 52: 218-223.
122. Lammers KM, Lu R, Brownley J et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008; 135: 194-204.
123. Fasano A, Not T, Wang W et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in celiac disease. Lancet 2000; 355: 1518-1519.
124. Sapone A, Bai JC, Ciacci C et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med 2012; 10: 13.
125. Huebener S, Tanaka CK, Uhde M et al. Specific nongluten proteins of wheat are novel target antigens in celiac disease humoral response. J Proteome Res 2015; 14: 503-511.
126. Sapone A, Lammers KM, Casolaro V et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med 2011; 9: 23.
127. Brottveit M, Beitnes A-CR, Tollefsen S et al. Mucosal cytokine response after short-term gluten challenge in celiac disease and non-celiac gluten sensitivity. Am J Gastroenterol 2013; 108: 842-850.
128. Hollon J, Puppa EL, Greenwald B et al. Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity. Nutrients 2015; 7: 1565-1576.
129. Andre C, Andre F, Colin L et al. Measurement of intestinal permeability to mannitol and lactulose as a means of diagnosing food allergy and evaluating therapeutic effectiveness of disodium cromoglycate. Ann Allergy 1987; 59: 127-130.
130. Ventura MT, Polimeno L, Amoruso AC et al. Intestinal permeability in patients with adverse reactions to food. Dig Liver Dis 2006; 38: 732-736.
131. Perrier C, Corthesy B. Gut permeability and food allergies. Clin Exp Allergy 2011; 41: 20-28.
132. Jaervinen KM, Konstantinou GN, Pilapil M et al. Intestinal permeability in children with food allergy on specific elimination diets. Pediatr Allergy Immunol 2013; 24: 589-595.
133. Mullin JM, Gabello M, Murray LJ et al. Proton pump inhibitors: actions and reactions. Drug Discov Today 2009; 14: 647-660.
134. Keszthelyi D, Jansen S V, Schouten GA et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: A case-control study. Aliment Pharmacol Ther 2010; 32: 1124-1128.
135. Aydin C, Sarac B, Koyuncu A et al. Relaxant effect of omeprazole and lansoprazole in guinea pig gallbladder muscle strips in vitro. J Gastroenterol 2003; 38: 765-771.
136. Gabello M, Valenzano MC, Zurbach EP et al. Omeprazole induces gastric transmucosal permeability to the peptide bradykinin. World J Gastroenterol 2010; 16: 1097.
137. Murray LJ, Gabello M, Rudolph DS et al. Transmucosal gastric leak induced by proton pump inhibitors. Dig Dis Sci 2009; 54: 1408-1417.
138. Hopkins AM, McDonnell C, Breslin NP et al. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J Pharm Pharmacol 2002; 54: 341-347.
139. Mullin JM, Valenzano MC, Whitby M et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008; 28: 1317-1325.
140. Gabello M, Valenzano MC, Barr M et al. Omeprazole induces gastric permeability to digoxin. Dig Dis Sci 2010; 55: 1255-1263.
141. Yenioehirli A, Onur R. Specific H+/K+-ATPase inhibitors decreased contractile responses of isolated rat vas deferens. Pharmacol Res 2006; 54: 397-405.
142. Tachechi I, Kopacova M, Rejchrt S et al. Non-steroidal anti-inflammatory drug induced injury to the small intestine. Acta Med 2010; 53: 3-11.
143. Higuchi K, Umegaki E, Watanabe T et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-888.
144. Bjarnason I, So A, Levi AJ et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 324: 1171-1174.
145. Bjarnason I, Price AB, Zanelli G et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology 1988; 94: 1070-1074.
146. Darling RL, Romero JJ, Dial EJ et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 2004; 127: 94-104.
147. Somasundaram S, Sigthorsson G, Simpson RJ et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000; 14: 639.
148. Somasundaram S, Rafi S, Hayllar J et al. Mitochondrial damage: A possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-353.
149. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2005; 21: 169-175.
150. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-117.
151. Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut 2008; 57: 145-148.
152. Whittle BJR. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 2004; 500: 427-439.
153. Bjarnason I,Williams P, Smethurst P et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292-1297.
154. Sigthorsson G, Simpson RJ, Walley M et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-1923.
155. Smecuol E, Bai JC, Sugai E et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001; 49: 650-655.
156. Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J. Gastroenterol. 2009; 44: 23-29
157. Bjarnason I, Prouse P, Smith T et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; 330: 711-714.
158. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985; 290: 347-349.
159. Bjarnason I, Smethurst P, Fenn CG et al. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989; 34: 407-411.
160. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993; 38: 417-425.
161. Morris AJ, Murray L, Sturrock RD et al. Short report: The effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther 1994; 8: 343-346.
162. Bours MJ, Troost FJ, Brummer R-JM et al. Local effect of adenosine 5'-triphosphate on indomethacin-induced permeability changes in the human small intestine. Eur J Gastroenterol Hepatol 2007; 19: 245-250.
163. Bours MJL, Bos HJ, Meddings JB et al. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: A randomized cross-over study. BMC Gastroenterol 2007; 7: 23.
164. Troost FJ, Saris WHM, Brummer RJM. Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 2003; 57: 1579-1585.
165. van Wijck K, Verlinden TJM, van Eijk HMH et al. Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial. Clin Nutr 2013; 32: 245-251.
166. Clarke LL. A guide to Ussing chamber studies of mouse intestine. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1151-G1166.
167. de Magistris L, Familiari V, Pascotto A et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 2010; 51: 418-424.
168. Maes M, Kubera M, Leunis J-C et al. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012; 141: 55-62.
169. Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res 2016; 176: 23-35.
170. Severance EG, Gressitt KL, Stallings CR et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013; 148: 130-137.
171. Berk M, Williams LJ, Jacka FN et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013; 11: 200.
172. Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984; 1: 179-182.
173. Pals KL, Chang RT, Ryan AJ et al. Effect of running intensity on intestinal permeability. J Appl Physiol 1997; 82: 571-576.
174. van Nieuwenhoven MA, Brouns F, Brummer RJ. Gastrointestinal profile of symptomatic athletes at rest and during physical exercise. Eur J Appl Physiol 2004; 91: 429-434.
175. Maxton DG, Menzies IS, Slavin B et al. Small-intestinal function during enteral feeding and starvation in man. Clin Sci 1989; 77: 401-406.
176. Dean P, Kenny B. Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol Microbiol 2004; 54: 665-675.
177. Viswanathan VK, Koutsouris A, Lukic S et al. Comparative analysis of EspF from enteropathogenic and enterohemorrhagic Escherichia coli in alteration of epithelial barrier function. Infect Immun 2004; 72: 3218-3227.
178. Roxas JL, Koutsouris A, Bellmeyer A et al. Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner. Lab Investig 2010; 90: 1152-1168.
179. Bertelsen LS, Paesold G, Marcus SL et al. Modulation of chloride secretory responses and barrier function of intestinal epithelial cells by the Salmonella effector protein SigD. Am J Physiol Physiol 2004; 287: C939-C948.
180. Boyle EC, Brown NF, Finlay BB. Salmonella enterica serovar Typhimurium effectors SopB, SopE, SopE2 and SipA disrupt tight junction structure and function. Cell Microbiol 2006; 8: 1946-1957.
181. Amieva MR, Vogelmann R, Covacci A et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003; 300: 1430-1434.
182. Krueger S, Hundertmark T, Kuester D et al. Helicobacter pylori alters the distribution of ZO-1 and p120ctn in primary human gastric epithelial cells. Pathol Pract 2007; 203: 433-444.
183. Romanov V, Whyard TC, Waltzer WC et al. A claudin 3 and claudin 4-targeted Clostridium perfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells. Cancer Lett 2014; 351: 260-264.
184. Forrest JC, Campbell JA, Schelling P et al. Structure-function analysis of reovirus binding to junctional adhesion molecule 1 implications for the mechanism of reovirus attachment. J Biol Chem 2003; 278: 48434-48444.
185. Lopez S, Arias CF. Multistep entry of rotavirus into cells: A Versaillesque dance. Trends Microbiol 2004; 12: 271-278.
186. Nava P, Lopez S, Arias CF et al. The rotavirus surface protein VP8 modulates the gate and fence function of tight junctions in epithelial cells. J Cell Sci 2004; 117: 5509-5519.